Inhalable pharmaceutical formulation, apparatus, and use
By using lactose or its hydrate as a solid carrier in inhaled pharmaceutical formulations in combination with environmentally friendly propellants, the problems of drug particle aggregation and dosage inconsistency are solved, achieving stable and uniform drug delivery, which is suitable for the treatment of asthma and COPD.
Patent Information
- Application Number
- PCT/CN2025/093063
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Filing Date
- 2025-05-07
- Publication Date
- 2026-11-12
AI Technical Summary
Existing inhaled pharmaceutical formulations are prone to drug particle aggregation or flocculation when using hydrofluoroalkane propellants, leading to mechanical failures and dosage inconsistencies. Furthermore, traditional surfactants fail in non-CFC propellants, affecting drug delivery stability.
Lactose or its hydrate is used as a solid carrier, its particle size distribution is controlled and it is combined with hydrofluorocarbon propellants to form an inhaled pharmaceutical formulation, reducing the use of excipients, avoiding drug particle aggregation, and using environmentally friendly propellants such as HFA-152a and HFO-1234ze.
It achieves stable dispersion of drug particles, avoids mechanical failures and dosage inconsistencies, maintains the stability and uniformity of drug delivery, and meets environmental protection requirements.
Smart Images

Figure PCTCN2025093063-FTAPPB-I100001 
Figure PCTCN2025093063-FTAPPB-I100002 
Figure PCTCN2025093063-FTAPPB-I100003
Abstract
Description
Inhaled pharmaceutical preparations, devices and their uses Technical Field
[0001] This application relates to an inhaled pharmaceutical preparation, and an apparatus and use thereof. Specifically, this application relates to an inhaled pharmaceutical preparation that delivers at least two pharmaceutically active ingredients, and an apparatus and use thereof. Background Technology
[0002] With the increasing urbanization and globalization, bringing about health and environmental problems, respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD) have gradually become important health conditions that all of humanity needs to actively address. Studies have indicated that the prevalence of asthma has increased since the COVID-19 pandemic, due to pathophysiological damage to the respiratory tract caused by viral infection, particularly the upper respiratory tract and bronchi. Research also shows that patients with COPD have a 3.8 times higher risk of death than those without COPD.
[0003] Since asthma, COPD, and COVID-19 all involve lung damage, treatments that deliver the active pharmaceutical ingredient directly to the site of action are ideal. The optimal approach is to use inhaled medications to improve, control, and reduce epithelial damage and / or improve T-cell responses, thereby treating asthma and COPD while simultaneously providing beneficial regulatory effects against the COVID-19 pandemic. In this context, the choice of inhaler system will influence the direction of drug formulation development. Common inhalers include nasal sprays (NS), dry powder inhalers (DPI), soft mist inhalers (SMI), and metered-dose inhalers (MDI). Metered-dose inhalers can deliver medications in dissolved or suspended form. Typically, when activated, a metered-dose inhaler uses a relatively high vapor pressure propellant to expel aerosolized particles containing the active agent into the respiratory tract. Dry powder inhalers typically rely on forceful inhalation by the patient to deliver the dry powder medication into the respiratory tract. On the other hand, a sprayer creates an aerosol of the drug to be inhaled by energizing a liquid solution or suspension.
[0004] A metered-dose inhaler (MDI) is an active delivery device that uses propellant pressure. The propellant is a compressed gas; the medication and solvents mixed within it are released from the pressurized container, forming an aerosolized drug mist that enters the respiratory tract. Propellants are often chlorofluorocarbons (CFCs) because of their low toxicity and ideal vapor pressure, making them suitable for formulating stable medications. However, traditional CFC propellants are considered to have negative environmental impacts and are currently banned in most countries worldwide. Therefore, more environmentally friendly propellants have been developed as alternatives, such as perfluorinated compounds (PFCs) and hydrofluorocarbons (HFAs).
[0005] However, some metered-dose inhalers using hydrofluoroalkane propellants must be packaged in a small bag along with a desiccant to prevent moisture absorption, such as the following commercially available products: Advair (trade name: Serolat) (fluticasone / salmeterol), Flovent (fluticasone propionate), Symbicort (trade name: Symbicort) (budesonide / formoterol), Ventolin (trade name: Ventolin) (salbutamol sulfate), etc.
[0006] In addition, some metered-dose inhalers contain ethanol and therefore do not require moisture protection, such as the commercially available Proventil HFA and Proair. However, inhaled medications containing ethanol may have the following disadvantages: (1) some users cannot tolerate the taste and smell of alcohol; (2) some users cannot use it due to religious factors (such as Muslims); and (3) some users are unwilling to use it (such as patients with alcohol poisoning or children).
[0007] Active agents intended for delivery via suspension MDIs are typically provided as fine particles dispersed within a propellant or a combination of two or more propellants. To form these fine particles, the active agent is usually micronized. Fine particles suspended in a propellant or propellant system tend to aggregate or flocculate rapidly. This is particularly pronounced for active agents in micronized form. Such aggregation or flocculation of fine particles can further complicate the delivery of the active agent. For example, aggregation or flocculation can cause mechanical failures, such as malfunctions caused by blockage of valve orifices in aerosol containers. Undesirable aggregation or flocculation of drug particles can also cause rapid sedimentation or agglomeration of drug particles, and this behavior can lead to inconsistent dosing delivery, which can be particularly problematic for high-potency, low-dose agents. Another issue associated with these suspension MDI formulations concerns the growth of drug crystals during storage, leading to a decrease in aerosol properties and dosing uniformity of MDI delivery over time.
[0008] In traditional CFC systems, when the active agent present in MDI dissolves in the propellant or propellant system, a surfactant is often applied to the surface of the active agent to reduce or prevent aggregation problems and maintain a substantially homogeneous dispersion. The use of surfactants in this manner is sometimes referred to as stabilizing the suspension. However, many surfactants that are soluble and effective in CFC systems are ineffective in HFA and PFC systems because these surfactants exhibit different solubility characteristics in non-CFC propellants. Summary of the Invention
[0009] The purpose of this application is to provide an inhaled pharmaceutical preparation, as well as an apparatus and uses for using the inhaled pharmaceutical preparation. The inhaled pharmaceutical preparation can effectively deliver two or more active pharmaceutical ingredients simultaneously and can be used in conjunction with a low-ozone-consuming propellant. Furthermore, the inhaled pharmaceutical preparation provided in this application, while reducing the use of excipients and adding microparticles, still avoids the problems of drug particle aggregation or flocculation, and exhibits good stability and consistency.
[0010] In view of the above problems, this application provides an inhaled pharmaceutical formulation containing lactose or its hydrate as carrier particles for microparticles, wherein the lactose or its hydrate has a specific particle size and concentration, thereby improving the problems of machine malfunction and inconsistent delivery dosage caused by drug particle aggregation in inhaled pharmaceutical formulations while reducing the use of excipients.
[0011] On the one hand, this application provides an inhaled pharmaceutical formulation comprising: a propellant; at least two active pharmaceutical ingredients; and a solid carrier.
[0012] On the other hand, this application provides an inhaled pharmaceutical preparation which is essentially composed of a propellant, at least two active pharmaceutical ingredients, and a solid carrier.
[0013] In some embodiments, the solid carrier may be lactose or its hydrate, cellulose or its derivative, starch or its derivative, glucose, sorbitol, mannitol, maltitol, xylitol, or a mixture thereof. Preferably, lactose or its hydrate is used; more preferably, lactose monohydrate is used. Lactose may be present as α-lactose monohydrate, β-lactose monohydrate, or a mixture of both; or anhydrous α- or β-lactose or a mixture thereof may be used; or amorphous lactose may be used.
[0014] On the other hand, this application provides an inhaled pharmaceutical preparation that is essentially composed of a propellant, at least two pharmaceutically active ingredients, and a solid carrier, wherein the solid carrier is selected from lactose or its functional analogues.
[0015] On the other hand, this application provides an inhaled pharmaceutical preparation that is essentially composed of a propellant, at least two pharmaceutical active ingredients, and a solid carrier, wherein the solid carrier is selected from lactose monohydrate, and the hydrate may be polycrystalline, amorphous, or a mixture thereof.
[0016] In some embodiments, the particle size D of the lactose or its hydrate is... 90 (90% cumulative particle distribution) not greater than 150 μm, D 50 (Particle cumulative distribution 50%) not greater than 75 μm, D 10 (Particle cumulative distribution 10%) not greater than 10 μm. In some embodiments, the particle size D of the lactose or its hydrate is... 90 No larger than 70μm, D 50 No larger than 35μm, D 10 Not greater than 2 μm. In some embodiments, the particle size D of the lactose or its hydrate is... 90 No larger than 50μm, D 50 No larger than 20μm, D 10 Not greater than 5 μm. In some embodiments, the particle size D of the lactose or its hydrate is... 90 No larger than 50μm, D 50 No larger than 20μm, D 10 Not greater than 3 μm. In some embodiments, the particle size D of the lactose or its hydrate is... 90 No larger than 10μm, D 50 No larger than 5μm, D 10 No larger than 1 μm.
[0017] In some embodiments, the propellant is a hydrofluoroalkane compound.
[0018] On the other hand, the inhaled pharmaceutical formulation of this application includes a propellant component, wherein the propellant component comprises 1,1-difluoroethane (HFA152a).
[0019] On the other hand, the inhaled pharmaceutical formulation of this application includes a propellant component, wherein the propellant component comprises tetrafluoropropylene (HFO-1234ze(E)).
[0020] In some embodiments, the active pharmaceutical ingredient is selected from a combination of at least two of the following: corticosteroids, beta-2 adrenergic agonists, anticholinergics, anti-allergic drugs, anti-inflammatories, bronchodilators, bronchoconstrictors, pulmonary lung surfactants, antibiotics, leukotriene inhibitors, leukotriene antagonists, mast cell inhibitors, and antihistamines, and any pharmaceutically acceptable salts thereof. In some embodiments, the active pharmaceutical ingredient may be selected from a combination of any two of corticosteroids, beta-2 adrenergic agonists, and anticholinergics. In some implementations, the two active pharmaceutical ingredients are a combination of a corticosteroid and a short-acting beta-2 adrenergic agonist (SABA).
[0021] In some embodiments, the concentrations of the at least two active pharmaceutical ingredients are both less than about 0.3% w / w (weight percentage).
[0022] In some embodiments, the lactose or its hydrate in the formulation is present in an amount of about 0.1% w / w to about 1.5% w / w. In some embodiments, the lactose or its hydrate in the formulation is present in an amount of about 0.1% w / w to about 1.2% w / w. In some embodiments, the lactose or its hydrate in the formulation is present in an amount of about 0.3% w / w to about 1.2% w / w. In some embodiments, the lactose or its hydrate in the formulation is present in an amount of about 0.5% w / w to about 1.2% w / w. In some embodiments, the lactose or its hydrate in the formulation is present in an amount of about 0.8% w / w to about 1.2% w / w. In some embodiments, the lactose or its hydrate in the formulation is present in an amount of about 0.1% w / w to about 1.0% w / w.
[0023] In some embodiments, the particle size D of the lactose or its hydrate is... 90 No larger than 50μm, D 50 The size of the lactose is not greater than 20 μm, the D10 is not greater than 5 μm, and the content of the lactose or its hydrate in the formulation is from about 0.8% (w / w) to about 1.2% (w / w).
[0024] In some embodiments, the active pharmaceutical ingredient is a combination of a corticosteroid and a short-acting beta-glucosidase synergist.
[0025] In some embodiments, the corticosteroid is beclomethasone, budesonide, ciclesonide, flunisolone, fluticasone, methylprednisolone, mometasone, prednisone, triamcinolone, or a pharmaceutically acceptable salt thereof;
[0026] In some implementations, the short-acting beta-glyoxal synergist is bitolterol, carbuterol, fenoterol, hexoprenaline, isoproterenol, levosabutamol, orciprenaline, pirbuterol, procaterol, rimiterol, salbutamol, terbutaline, tulobuterol, reproterol, ipratropium, epinephrine, or a pharmaceutically acceptable salt thereof.
[0027] In some embodiments, the corticosteroid is budesonide, and it is present in the formulation at a concentration of 0.18% (w / w) to 0.2% (w / w).
[0028] In some embodiments, the short-acting ethylenediamine synergist is salbutamol sulfate, and its content in the formulation is from 0.25% (w / w) to 0.28% (w / w).
[0029] On the other hand, this application provides an inhalation device comprising:
[0030] Actuator; and
[0031] Aerosol cans for filling the inhaled pharmaceutical formulations of this application;
[0032] The actuator includes a housing and a nozzle block for a metering valve;
[0033] One end of the housing is open to accommodate the aerosol can, and the other end is open to form an airflow-through chamber for introducing the inhaled pharmaceutical preparation into the patient's oral cavity and / or nasal cavity.
[0034] The nozzle block has an orifice channel that communicates with a dispensing valve and is used to guide the inhaled pharmaceutical preparation from the dispensing valve into the chamber.
[0035] On the other hand, this application provides the use of the above-mentioned inhaled pharmaceutical preparation in the manufacture of a medicament for treating lung diseases. In some embodiments, the lung disease is asthma or chronic obstructive pulmonary disease.
[0036] On the other hand, this application provides a method for treating lung diseases, which includes administering the aforementioned inhaled pharmaceutical preparation. In some embodiments, the lung disease is asthma or chronic obstructive pulmonary disease.
[0037] In some embodiments, the inhaled pharmaceutical formulation of this application maintains good drug particle dispersion while reducing the use of excipients. This not only avoids drug particle aggregation and adhesion to the container but also allows for effective delivery of the drug to the lungs via respiration. In some embodiments, the inhaled pharmaceutical formulation of this application shows virtually no increase in the size or change in the crystal morphology of the active pharmaceutical ingredient particles over a relatively long period. Therefore, the drug particles can be easily redispersed without affecting the reproducibility of the drug delivery dose. In some embodiments, the inhaled pharmaceutical formulation of this application maintains good drug uniformity during use, maintaining a uniform dose even with multiple sprays. In some embodiments, the inhaled pharmaceutical formulation of this application exhibits good storage stability, meeting pharmaceutical regulatory requirements. Detailed Implementation
[0038] The following further describes the embodiments of this application. This application is not limited to a solution that fully includes the structure described below. The following description is only used to illustrate the details of this application and the effects of its implementation.
[0039] The definitions used in this application are based on the generally accepted definitions in the field of pharmaceutical technology and apply throughout the specification, unless otherwise specified in the specification based on specific circumstances.
[0040] The inhaled pharmaceutical formulation of this application includes the use of a solid carrier, which may be lactose or its hydrate, existing in a particulate form; the lactose or its hydrate may be crystalline or amorphous; it may be α-state or β-state or a mixture of both; preferably, it is lactose monohydrate or lactose monohydrate. The particulate form of the lactose or its hydrate used in this application can be described by particle size and particle size distribution. The solid carrier used in this application has a particle size distribution D... 90 No larger than 150μm, D 50 No larger than 75μm, D 10 Not greater than 10 μm; preferably, the cumulative particle size distribution D 90 No larger than 70μm, D 50 No larger than 35μm, D 10 Not greater than 5 μm; preferably, the cumulative particle size distribution D 90 No larger than 50μm, D 50 No larger than 20μm, D 10 No larger than 2μm.
[0041] The inventors have discovered that, in order to achieve the purpose of this application, the content of lactose or its hydrate in the inhaled pharmaceutical formulation of this application is from about 0.1% w / w (weight percentage) to about 1.5% w / w (weight percentage); preferably from about 0.1% w / w (weight percentage) to about 1.2% w / w (weight percentage); preferably from about 0.3% w / w (weight percentage) to about 1.2% w / w (weight percentage); preferably from about 0.5% w / w (weight percentage) to about 1.2% w / w (weight percentage); preferably from about 0.8% w / w (weight percentage) to about 1.2% w / w (weight percentage); preferably from about 0.1% w / w (weight percentage) to about 1.0% w / w (weight percentage).
[0042] Those skilled in the art understand that in suspensions, the smaller the drug particles, the higher the surface area to volume ratio, the more prone they are to thermodynamic instability, providing significantly high surface free energy and thus promoting particle aggregation. It is generally accepted that particle aggregation and adhesion of such particles to the inhaler wall can cause particles to leave the inhaler as large and stable agglomerates, or prevent particles from leaving the inhaler and remain adhered to its interior, even leading to inhaler blockage or occlusion. Therefore, if drug particle aggregation is not controlled, the valves of the inhalation device may become clogged, resulting in inaccurate dispensing and, more seriously, malfunction of the inhalation device. Furthermore, drug particle aggregation can also cause rapid emulsification or precipitation of the suspension, and the resulting phase separation may not be resolved even with vigorous shaking, making it difficult to control the patient's condition. This application improves drug particle aggregation by adding lactose or its hydrate with a specific particle size distribution and concentration as a carrier particle for the drug particles, thereby improving the problems of inhaler blockage and inaccurate drug dispensing.
[0043] The formulations, apparatus, methods, systems, or combinations thereof of this application contain at least a pharmaceutically acceptable propellant. The propellant is selected from materials that have no significant negative impact on ozone and are substantially pharmaceutically harmless. Preferably, the propellant comprises at least one hydrofluoroalkane compound. In some embodiments, the propellant used in the formulations, apparatus, methods, systems, or combinations thereof of this application has a content in the pharmaceutical formulation greater than about 90% w / w (weight percentage), preferably greater than 95% w / w (weight percentage), and more preferably greater than about 98% w / w (weight percentage).
[0044] Compared to some commonly used chlorofluorocarbons, the formulations, apparatus, methods, systems, or combinations thereof of this application, although containing propellants, result in very low or negligible ozone depletion, thus having the advantage of essentially not causing ozone depletion. In some embodiments, in addition to the preferred hydrofluoroalkane, the pharmaceutical formulations of this application may further contain one or more other hydrofluoroolefins, hydrofluoroalkanes, perfluorocarbons, fluorocarbons, hydrocarbons, alcohols, ethers, or mixtures thereof, provided that they do not affect the therapeutic effect and stability of the present invention, or that their use does not violate laws and environmental regulations, provided that such contents do not exceed 1% w / w (weight percentage) of the total, preferably not more than 0.5% w / w (weight percentage), and more preferably not more than 0.1% w / w (weight percentage).
[0045] This application provides a method for improving the stability of a pharmaceutical preparation comprising a composition of a propellant component and at least two active ingredients, wherein the propellant component comprises 1,1-difluoroethane (HFA152a); preferably, the propellant is substantially HFA-152a, or a composition substantially composed of HFA-152a.
[0046] On the other hand, this application provides a method for improving the stability of a pharmaceutical preparation comprising a composition of a propellant component and at least two active ingredients, wherein the propellant component comprises tetrafluoropropylene (HFO-1234ze(E)); preferably, the propellant is substantially HFO-1234ze(E), or a composition substantially composed of HFO-1234ze(E).
[0047] Optionally, the ingredients and conditions used to prepare the pharmaceutical formulation of this application maintain the water content of the pharmaceutical formulation at less than 100 ppm based on the total weight of the drug, preferably less than 50 ppm, more preferably less than 10 ppm, and particularly preferably less than 5 ppm.
[0048] The preparation of pharmaceutical formulations with the aforementioned low water content, as required, involves using propellant components with appropriately low water content, followed by preparation of the pharmaceutical formulation of this application under appropriate drying conditions. Preparation of pharmaceutical formulations under appropriate drying conditions is well known in the art, and the techniques involved are fully understood by those skilled in the art. Other steps to obtain low water content in the product include drying canisters and valve components and storing them in a controlled humidity environment before and during device assembly.
[0049] In some embodiments, this application provides a pharmaceutical preparation, preferably a pharmaceutical preparation capable of forming a drug aerosol, which, when combined with a device, can form a system or combination for use at a specific site within the body of a subject requiring treatment, or for achieving a therapeutic effect by delivery to a preferred site within the body of the subject requiring treatment. The subject requiring treatment can be a human or other mammal. The device can be a metered-dose inhaler, a nasal spray, or a nebulizer, preferably a metered-dose inhaler.
[0050] The pharmaceutical formulations of this application are suitable for delivery via the mouth, nose, and / or other mucous membranes. Preferably, the inhaled pharmaceutical formulations of this application can be delivered orally to treat diseases occurring in the lungs. This application can be used in conjunction with metered-dose inhaler systems or combinations to meet the needs of treating asthma, COPD, or COVID-19.
[0051] In some embodiments, this application provides an inhalation device that delivers the pharmaceutical preparation of this application through breathing. The inhalation device includes an actuator (or mouthpiece) and a container.
[0052] The actuator described above includes a housing with one end open to fit into the container and the other end open to form an airflow-through chamber for introducing medication into the patient's oral cavity and / or nasal cavity. The chamber is preferably suitable for use by the patient in a mouthpiece or oral-holding manner. The actuator may also include a nozzle block receiving a dispensing valve (described later), the nozzle block having an orifice channel communicating with the dispensing valve for guiding medication from the valve into the chamber.
[0053] The aforementioned container is used to contain the pharmaceutical formulation of this application and has a dispensing valve operable between a non-dispensing position and a dispensing position, the dispensing valve being engageable with the nozzle block. The container can be made of aluminum, glass, stainless steel, or plastic. Further, the container may have one or more internal coating layers. In some embodiments, the container is preferably an aerosol can.
[0054] In some embodiments, the inhalation device of this application may be further configured with a counter or a dose display. The inhalation device of this application is preferably a metered-dose inhaler.
[0055] The inhalation device described in this application is a metered-dose inhaler (MDI). Upon actuation, the MDI expels propellant along with the drug through pressure changes. The propellant vaporizes and disperses the drug, producing a sufficiently fine aerosol. Combined with the user's breathing, this aerosol effectively delivers the drug to the lungs. The physical processes involved in converting a drug solution or suspension into a fine aerosol by the MDI are complex: one is the turbulent flow fragmentation of the jet fluid, characterized by disordered changes in pressure and velocity, resulting in unstable and transient disturbances occurring in three-dimensional space; the other is the decrease in ambient pressure around the propellant, leading to flash distillation (or flash evaporation) as the boiling point drops below the ambient temperature. Regardless of the mechanism, the aerosol particles produced by the MDI need to reach the target site, the lungs, through respiration. The particle size distribution affects the drug distribution in the lungs, which in turn affects the therapeutic effect. Those skilled in the art will understand that the particle size of aerosol particles can be described by the mass median aerodynamic diameter (MMAD), and the deposition momentum distribution of this particle can be measured to determine the deposition location of the particles in the lung region.
[0056] Furthermore, for such formulations to reach deep into the lungs through inhalation, the active ingredient must be in very fine particulate form, for example, with a median mass aerodynamic diameter (MMAD) of less than 10 μm. Particles with an MMAD greater than 10 μm may impinge on the throat wall and typically do not reach the lungs. Particles with an MMAD in the range of 2 μm to 5 μm usually deposit in the respiratory bronchioles. Particles with an MMAD in the range of 0.05 μm to 3 μm may deposit in the alveoli or be absorbed into the bloodstream.
[0057] In some embodiments, the pharmaceutical preparations, devices, methods, systems, or combinations thereof provided in this application are used for local administration of medications for treating respiratory diseases. In some embodiments, the suspension or solution formed by the active pharmaceutical ingredient and propellant of this application, through appropriate pressure and propellant, controls the MMAD (microscopic anatomy and ductility) of the drug aerosol particles within a range suitable for pulmonary treatment. This MMAD range is preferably controlled within the range of about 0.5 μm to 5 μm, more preferably within the range of about 1 μm to 4.5 μm, more preferably within the range of about 1.2 μm to 4.2 μm, and even more preferably within the range of about 1.5 μm to 4.15 μm.
[0058] In some embodiments, when this application is used to treat lung diseases, the active pharmaceutical ingredient may or may not be in a micronized or particulate form. In some embodiments, preferably, the active pharmaceutical ingredient is in a micronized or particulate form. For example, it may have a particle size D. 90 Micronized or particulate forms smaller than approximately 10 micrometers, preferably with a drug particle size D 90 Smaller than approximately 5.5 micrometers, more preferably, the drug particle size D 90 It is in the range of approximately 4.0 to 5.3 micrometers.
[0059] The pharmaceutical formulations, devices, methods, systems, or combinations thereof provided in this application contain at least two active pharmaceutical ingredients. Those skilled in the art understand that, compared to formulations containing only a single pharmaceutical ingredient, when a single formulation contains two or more active pharmaceutical ingredients, the addition of different types of active pharmaceutical ingredients and the selection of different propellants can lead to unpredictable changes in the particle size distribution characteristics, stability, uniformity of each delivered dose, and the proportion of each delivered dose. Formulating pharmaceutical compositions with two or more active pharmaceutical ingredients is more challenging than formulating a single-ingredient formulation. In addition to considering the interactions between two or more drugs, it is also a significant challenge to consider and adjust the uniformity, proportion, and absorption site distribution of the two or more drugs in terms of delivery dose. This application provides a formulation, method, system, device, or combination thereof that can simultaneously deliver two or more drugs, and the therapeutically effective dose can be selected to be relatively lower than the therapeutically effective dose required for any single drug delivery, thereby further avoiding or reducing potential medical side effects, while simultaneously achieving a faster onset of action or a longer duration of action.
[0060] The pharmaceutical preparations, devices, methods, systems, or combinations thereof provided in this application may contain two or more active pharmaceutical ingredients selected from corticosteroids, long-acting beta-2 adrenergic agonists (LABA), short-acting beta-2 adrenergic agonists (SABA), long-acting anticholinergics (LAMA), short-acting anticholinergics (SAMA), anti-allergic drugs, anti-inflammatory drugs, bronchodilators, bronchoconstrictors, pulmonary lung surfactants, antibiotics, leukotriene inhibitors or antagonists, and mast cell inhibitors. Inhibitors or antihistamines, etc. The active pharmaceutical ingredient used in this application is preferably a corticosteroid, a long-acting beta-2 adrenergic agonist (LABA), a short-acting beta-2 adrenergic agonist (SABA), a long-acting anticholinergic (LAMA), or a short-acting anticholinergic (SAMA).
[0061] In some embodiments, this application provides an apparatus, method, system, or combination thereof suitable for treating lung diseases, comprising an actuator and an aerosol can filled with an aerosol formulation, which may be a suspension or a solution. In some embodiments, the aerosol formulation is preferably a suspension. In some embodiments, the aerosol formulation contains two pharmaceutically active ingredients; the pharmaceutically active ingredients are selected from corticosteroids, long-acting beta-2 adrenergic agonists (LABA), short-acting beta-2 adrenergic agonists (SABA), long-acting anticholinergics (LAMA), and short-acting anticholinergics (SAMA). Preferably, the two active pharmaceutical ingredients are a combination of a corticosteroid and a beta-2 adrenergic agonist (SABA), more preferably a combination of a corticosteroid and a short-acting beta-2 adrenergic agonist (SABA). In some embodiments, the two active ingredients in the aerosol formulation may be simultaneously or separately in suspension or solution form. In some embodiments, one active pharmaceutical ingredient is a suspension and the other is a solution.
[0062] The active pharmaceutical ingredient in this application may be selected from beclomethasone, budesonide, ciclesonide, flunisolone, fluticasone, methylprednisolone, mometasone, prednisone, triamcinolone, bitolterol, carbuterol, fenoterol, hexoprenaline, isoproterenol, levosasalbutamol, orciprenaline, procaterol, ributerol, salbutamol, or procaterol.albuterol, terbutaline, tulobuterol, reproterol, ipratropium, epinephrine, bambuterol, clenbuterol, formoterol, salmeterol, carmoterol, milveterol, indacaterol, glycopyrrolate, dexipirronium, scopolamine, tropicamide, pirenzepine (nzepine), dimenhydrinate, tiotropium, darotropium, aclidinium, trospium, isipratropium, atropine, bezatropin, oxitropium, tripedane, cortisone, prednisone, prednisolone, dexamethasone, betamethasone, triamcinolone, or their configurational isomers, esters, salts, solvates, or combinations thereof. In some embodiments, the active pharmaceutical ingredient is preferably selected from beclomethasone, budesonide, ciclesonide, fluticasone, mometasone, carbuterol, fenoterol, levosalbutamol, procaterol, salbutamol, or...albuterol, tulobuterol, ipratropium, bambuterol, clenbuterol, formoterol, salmeterol, carmoterol, indacaterol, glycopyrrolate, tiotropium, aclidinium, or their configurational isomers, esters, salts, solvates, or combinations thereof. In some embodiments, the active pharmaceutical ingredient is further preferably budesonide, salbutamol or albuterol, and anticholinergic drugs, or their conformational isomers, esters, salts, or solvates, or combinations thereof; in some embodiments, the active pharmaceutical ingredient is more preferably budesonide or its conformational isomers (e.g., the 22R-conformity of budesonide), esters, salts, or solvates, in combination with salbutamol or albuterol, or their conformational isomers, esters, salts, or solvates. In some embodiments, a combination of budesonide and salbutamol sulfate or albuterol sulfate is even more preferred.
[0063] In some embodiments, the pharmaceutical preparations, devices, methods, systems or combinations thereof provided in this application, used to treat asthma or chronic obstructive pulmonary disease (COPD) via an inhalation device, comprise at least one pharmaceutically effective amount of a pharmaceutically active ingredient and at least one pharmaceutically acceptable propellant.
[0064] In some embodiments, the apparatus, method, system, or combination thereof provided in this application includes a container, which is an aerosol can containing a pharmaceutical preparation. The pharmaceutical preparation is a suspension or solution and contains at least two active pharmaceutical ingredients. The active pharmaceutical ingredient is a combination of budesonide or a conformational isomer (e.g., the 22R-conformation of budesonide), an ester, a salt, or a solvate, and salbutamol or albuterol or a conformational isomer, an ester, a salt, or a solvate. In some embodiments, a combination of budesonide and salbutamol sulfate or albuterol sulfate is preferred. In some embodiments, the dose of budesonide per spray after each actuation is in the range of about 70 μg to 100 μg, preferably about 80 μg per spray. In some embodiments, the dose of salbutamol (or albuterol) per spray after each actuation is in the range of about 75 μg to 100 μg, preferably about 90 μg per spray.
[0065] This application does not require the use of additional anti-coagulants or surfactants, such as polyethylene glycol (PEG) or polyvinylpyrrolidone (PVP), which can overcome the cohesive forces between drug particles. This application promotes the formation of drug particle suspensions with effects such as delayed sedimentation or delayed precipitation by adding lactose or its hydrates of specific particle size and concentration as carrier particles. Preferably, the formulations, apparatus, methods, systems, or combinations thereof of this application achieve suspension stability without the use of anti-coagulants or surfactants, and simultaneously promote better drug suspension dispersion.
[0066] In some embodiments, this application provides an formulation, method, system, or device or combination thereof suitable for treating lung diseases, which allows the drug to be dispensed with a uniform dose even when the drug is sprayed in multiple doses without strenuous shaking or agitation.
[0067] When a drug concentration of less than about 0.15% w / w (weight percentage) is used in this application, the drug is more likely to be under-delivered. When a drug concentration greater than about 0.15% w / w (weight percentage) but less than about 0.3% w / w (weight percentage) is used in the formulation of this application, it is sometimes found that the drug is more likely to meet the set dosage and is stable in the formulation, and therefore may have a tendency to increase the suspension time. As the drug concentration increases, for example, exceeding about 0.5% w / w (weight percentage), the drug generally tends to aggregate and accelerate sedimentation, the volume occupied by the drug also increases, and a rapid sedimentation effect is formed, which is detrimental to the uniformity of drug use. The drug concentration in the formulation of this application is preferably less than about 0.3% w / w (weight percentage).
[0068] In some embodiments, the pharmaceutical preparations, devices, methods, systems, or combinations thereof of this application can be used to treat inflammatory or obstructive lung diseases. This lung disease or condition can be selected from mild asthma, moderate asthma, severe asthma, bronchitic asthma, intrinsic (non-allergic) asthma, extrinsic (allergic) asthma, exercise-induced asthma, occupational asthma, asthma caused by bacterial infection, chronic obstructive pulmonary disease (COPD), chronic obstructive lung disease (COLD), chronic obstructive airway disease (COAD), chronic airflow limitation (CAL), chronic obstructive respiratory disease (CORD), worsening of airway hyperreactivity due to drug treatment, and allergic rhinitis. Rhinitis, sinusitis, pulmonary vasoconstriction, inflammation, allergies, impeded respiration, respiratory distress syndrome, pulmonary hypertension, pulmonary vasoconstriction, emphysema, cystic fibrosis, etc.
[0069] The terms “pharmaceutical active ingredient,” “drug,” and “pharmaceutical,” as used herein, are used broadly in the sense understood by one of ordinary skill in the art, referring to any material or substance that has, or is at least believed to have, curative or therapeutic properties, and can be used to relieve disease, heal injury or other ailment, and / or pain or other symptoms, and / or for diagnostic purposes. These terms include, for example, small molecule drugs and large molecule bioactive ingredients. In this application, these terms are also used to refer to combinations that are medically effective or at least believed to be effective.
[0070] As used in this article, "therapeutic effective amount" and "pharmaceutical effective amount" refer to the amount of a compound that achieves a therapeutic effect by preventively inhibiting or preventing the onset of a disease or condition. A therapeutic effective amount can be an amount that alleviates one or more symptoms of a patient's disease or condition to a certain extent, partially or completely restores one or more physiological or biochemical parameters that are associated with or cause the disease or condition to normal, and / or reduces the likelihood of the onset of the disease or condition.
[0071] The term “about” or “approximately” as used in this article means that for a given numerical value, such as a given proportion of active pharmaceutical ingredients, numerical value, particle size, particle diameter, particle size distribution characteristics, uniformity of delivery dose, etc., the indicated value contains a deviation within ±10%.
[0072] The term "particle size" can refer to a measurement of a single particle or the total particle distribution. For a single particle, it is typically expressed in units of length (e.g., nanometers (nm) or micrometers (μm). This type of parameter can be measured using a variety of techniques, including dynamic light scattering, static light scattering, laser diffraction, deposition, time-of-flight analysis, or any method well known to those skilled in the art. For example, using laser particle size analysis, the particle size is not measured individually, but rather by illuminating dispersed powder particles with laser light at different angles. Several diffraction projections obtained from a photosensitive element are then analyzed by overlaying, subtraction, and cross-analysis to calculate the statistical proportion of particles of various sizes. The term "D"... X "Particle cumulative distribution" indicates that X percent of all particles are smaller than this size, and can be used to quantify particle size distribution; therefore, D 90 The instrument indicates that 90% of the total particles are less than D. 90 The value following D represents the particle size; 50 The instrument indicates that 50% of the total particles are less than D. 50 The particle size represented by the subsequent numerical values follows the same logic. Additionally, the term "median particle size" is defined as the median particle size based on the equivalent volume of spherical particles; that is, dividing the overall particle size distribution in half, such that 50% of the total is greater than or less than this size, which is the D value referred to here. 50 From D XDerived descriptive methods, based on D 90 For example, it can also be represented as D(0.90) or D[0.9] or similar notation. The use of uppercase D or lowercase d is interchangeable and has the same meaning.
[0073] As used herein, the term "emitted dose" or "ED (Emitted Dose)" refers to the mass of the active pharmaceutical ingredient emitted from the device. Those skilled in the art will understand that the emitted dose ED is obtained and validated from a Dosage Unit Sampling Apparatus (DUSA).
[0074] As used herein, the term "fine particle dose" or "FPD" refers to the total mass of drug particles smaller than a certain aerodynamic diameter after the drug is emitted from the device. Unless otherwise specified, this aerodynamic diameter is generally considered to be 5 μm by those skilled in the art. In other words, unless a specific MMAD is specified, the FPD refers to the FPD value occupied by drug particles with an MMAD of less than 5 μm.
[0075] The term "fine particulate fraction" or "FPF" as used in this article refers to the proportion of a specific total MMAD value delivered relative to the total dose emitted, calculated by dividing FPD by ED.
[0076] The term “MMAD” as used herein refers to the median mass aerodynamic diameter, which is the aerodynamic diameter of aerosol particles. The calculation of MMAD is based on the United States Pharmacopoeia (USP), and the relevant content of the USP is incorporated into this application.
[0077] The term "propellant" as used in this article refers to a pharmacologically inert substance that produces a sufficiently high vapor pressure at normal room temperature to propel the drug from the canister into the patient's mouth during MDI actuation, allowing it to enter the lungs through the respiratory tract via the patient's breathing.
[0078] The term "inhalable" as used in this article generally refers to particles, aggregates, droplets, etc., that are small enough to be inhaled and reach the airways of the lungs.
[0079] As used herein, the term "suspension" refers to a substance that provides a continuous phase in which drug particles or drugs deposited on carrier particles can be dispersed to provide a co-suspension formulation. For example, the active pharmaceutical ingredient in this application, or the active pharmaceutical ingredient deposited on a solid carrier, is substantially insoluble in the solute or propellant and is presented as an aerosol formulation in particulate form.
[0080] As used in this article, "suspension stability" and "stable suspension" refer to suspension formulations that maintain the properties of active agent particles over a period of time. Suspension stability can be measured by the uniformity of delivered dosage.
[0081] The term “labeled dose (LD)” as used in this article refers to the mass of medication that can be delivered each time the inhalation device is activated, or the dose indicated on the inhaler packaging.
[0082] The term “geometric standard deviation (GSD)” used in this article refers to the dispersion of the measured particle size; it is defined as the ratio of the median particle size to the median particle size ± 1 standard deviation (σ). An aerosol with a GSD of 1.22 is considered a polydisperse aerosol, and most therapeutic aerosols are polydisperse aerosols with a GSD between 2 and 3.
[0083] Example
[0084] The raw materials, lactose micronization, chromatography conditions, drug delivery (DDU) test, and aerodynamic particle size distribution test used in the following examples are described below.
[0085] raw material
[0086] Micronized salbutamol sulfate was purchased from Cambrex (Paullo, Milan, Italy). Micronized budesonide was purchased from Chemo (Saronno, Varese, Italy). Lactohale lactose was purchased from DFE Pharma (Goch, Germany). HFA-152a and HFA1234ze(E) were purchased from a Taiwanese manufacturer. The DF316 / 50PRE7 metering valve was purchased from Aptar (UK). The 14ml fluorocarbon polymerization (FCP) coated aluminum can was purchased from H&T Presspart (UK). The commercially available product used as a reference standard was AztraZeneca Pharmaceuticals Inc.'s commercially available MDI.
[0087] Lactose micronization
[0088] The MicroJetMill instrument was purchased from Noozle Shanghai. It was used to manufacture lactose of different particle sizes. The MicroJetMill operates at air pressures ranging from 3 bar to 10 bar.
[0089] Chromatographic conditions
[0090] The high-performance liquid chromatography (HPLC) system consisted of an Agilent 1260 Infinity II chromatography system equipped with a VWD detector (both purchased from Agilent Technologies, California, USA). A HIQ sil C18 HS 5μm 4.6mm × 250mm column (Oligaga Ltd., Taiwan) was used. The UV detection bar wavelength was 220nm, changing to 240nm after 8 minutes. The retention time for salbutamol sulfate was 4.6 minutes, and for budesonide, it was 17.9 minutes and 18.5 minutes, respectively.
[0091] Drug delivery (DDU) trials
[0092] For drug delivery testing, Instrument A was used at a flow rate of 28.3 L / min (±5%), following the United States Pharmacopeia monograph (USP 601). Each sample underwent a four-stage purging process before sampling. After purging, two purging cycles were collected in a DUSA tube. Subsequently, the purging device and DUSA tube were rinsed with an appropriate amount of diluent. The rinse mixture was analyzed by HPLC.
[0093] Aerodynamic Particle Size Distribution (APSD) Test
[0094] The APSD detection system uses a next-generation impact sampler (NGI). This device is a tiered impact sampler with 7 stages and a micropore collector (MOC). Following the United States Pharmacopeia monograph (USP 601), the instrument was used at a flow rate of 30 L / min (±5%). Each cup of the impact sampler was coated with hexane (w / v) containing 1% silicone oil. After four starts, the cups were rinsed with an appropriate amount of diluent, and the rinse mixture was analyzed by HPLC.
[0095] Example 1: Contains two active particles, salbutamol sulfate and budesonide, and 0.1% micronized lactose (particle size distribution D). 90 No larger than 41μm, D 50 No larger than 16μm, D 10 Metered-dose inhalers (not larger than 2.7 μm)
[0096] The preparation steps for the metered-dose inhaler are as follows: First, weigh the required amount of the two active drug particles and 0.1% w / w (weight percentage) micronized lactose and place them in an FCP aluminum canister. After ultrasonically mixing for 10 minutes, seal the canister using the metering valve (crimping). Next, pour the required amount of HFA-152a into the sealed FCP aluminum canister through the metering valve, and then ultrasonically mix for another 10 minutes. As shown in Table 1, the drug particles in this mixture are suspended in the HFA-152a propellant.
[0097] Table 1. Pressurized inhalation suspension of salbutamol sulfate and budesonide, containing 0.1% w / w (by weight) lactose monohydrate and HFA-152a propellant.
[0098] Example 2: Contains two active particles, salbutamol sulfate and budesonide, and 0.5% micronized lactose (particle size distribution D). 90 No larger than 41μm, D 50 No larger than 16μm, D 10 Metered-dose inhalers (not larger than 2.7 μm)
[0099] The preparation steps for the metered-dose inhaler are the same as in Example 1, using 0.5% w / w (weight percentage) lactose monohydrate, as shown in Table 2, in which drug particles are suspended in HFA-152a propellant.
[0100] Table 2. Pressurized inhalation suspensions of salbutamol sulfate and budesonide, containing 0.5% w / w (weight percentage) lactose monohydrate and HFA-152a propellant.
[0101] Example 3: Contains two active particles, salbutamol sulfate and budesonide, and 0.8% w / w (weight percentage) lactose monohydrate (particle size distribution D). 90 No larger than 41μm, D 50 No larger than 16μm, D 10 Metered-dose inhalers (not larger than 2.7 μm)
[0102] The preparation steps for the metered-dose inhaler are the same as in Example 1. As shown in Table 3, the drug mixture is suspended in HFA-152a.
[0103] Table 3. Pressurized inhalation suspensions of salbutamol sulfate and budesonide, containing 0.8% w / w (weight percentage) lactose monohydrate and HFA-152a propellant.
[0104] Example 4: Contains two active particles, salbutamol sulfate and budesonide, and 1% w / w (weight percentage) lactose monohydrate (particle size distribution D). 90 No larger than 41μm, D 50 No larger than 16μm, D 10 Metered-dose inhalers (not larger than 2.7 μm)
[0105] The preparation steps for the metered-dose inhaler are the same as in Example 1. As shown in Table 4, the drug mixture is suspended in HFA-152a.
[0106] Table 4. Pressurized inhalation suspensions of salbutamol sulfate and budesonide, containing 1% w / w (by weight) lactose monohydrate and HFA-152a propellant.
[0107] Example 5: Contains two active particles, salbutamol sulfate and budesonide, and 1.2% w / w (weight percentage) lactose monohydrate (particle size distribution D). 90 No larger than 41μm, D 50 No larger than 16μm, D 10 Metered-dose inhalers (not larger than 2.7 μm)
[0108] The preparation steps for the metered-dose inhaler are the same as in Example 1. As shown in Table 5, the drug mixture is suspended in HFA-152a.
[0109] Table 5. Pressurized inhalation suspension of salbutamol sulfate and budesonide, containing 1.2% w / w (weight percentage) lactose monohydrate and HFA-152a propellant.
[0110] Example 6: Contains two active particles, salbutamol sulfate and budesonide, and 1.5% w / w (weight percentage) lactose monohydrate (particle size distribution D). 90 No larger than 41μm, D 50 No larger than 16μm, D 10 Metered-dose inhalers (not larger than 2.7 μm)
[0111] The preparation steps for the metered-dose inhaler are the same as in Example 1. As shown in Table 6, the drug mixture is suspended in HFA-152a.
[0112] Table 6. Pressurized inhalation suspension of salbutamol sulfate and budesonide, containing 1.5% w / w (by weight) lactose monohydrate and HFA-152a propellant.
[0113] Example 7: Contains two active particles, salbutamol sulfate and budesonide, and 0.1% w / w (weight percentage) lactose monohydrate (particle size distribution D). 90 No larger than 149μm, D 50 No larger than 72μm, D 10 Metered-dose inhalers (not larger than 9.3 μm)
[0114] The preparation steps for the metered-dose inhaler are as follows: First, weigh the required amount of the two active drug particles and 0.1% w / w (weight percentage) micronized lactose and place them in an FCP aluminum canister. After ultrasonically mixing for 10 minutes, seal the canister using the metering valve (crimping). Next, pour the required amount of HFA-152a into the sealed FCP aluminum canister through the metering valve, and then ultrasonically mix for another 10 minutes. As shown in Table 7, the drug particles in this mixture are suspended in the HFA-152a propellant.
[0115] Table 7. Pressurized inhalation suspension of salbutamol sulfate and budesonide, containing 0.1% w / w (weight percentage) lactose monohydrate and HFA-152a propellant.
[0116] Example 8: Contains two active particles, salbutamol sulfate and budesonide, and 0.5% w / w (weight percentage) lactose monohydrate (particle size distribution D). 90 No larger than 149μm, D 50 No larger than 72μm, D 10 Metered-dose inhalers (not larger than 9.3 μm)
[0117] The preparation steps for the metered-dose inhaler are the same as in Example 7. As shown in Table 8, the drug particles in this mixture are suspended in HFA-152a.
[0118] Table 8. Pressurized inhalation suspension of salbutamol sulfate and budesonide, containing 0.5% w / w (weight percentage) lactose monohydrate and HFA-152a propellant.
[0119] Example 9: Contains two active particles, salbutamol sulfate and budesonide, and 1% w / w (weight percentage) lactose monohydrate (particle size distribution D). 90 No larger than 149μm, D 50 No larger than 72μm, D 10 Metered-dose inhalers (not larger than 9.3 μm)
[0120] The preparation steps for the metered-dose inhaler are the same as in Example 7. As shown in Table 9, the drug particles in this mixture are suspended in HFA-152a.
[0121] Table 9. Pressurized inhalation suspensions of salbutamol sulfate and budesonide, containing 1% w / w (by weight) lactose monohydrate and HFA-152a propellant.
[0122] Example 10: Contains two active particles, salbutamol sulfate and budesonide, and 1% w / w (weight percentage) lactose monohydrate (particle size distribution D). 90 No larger than 10μm, D 50 No larger than 4μm, D10 Metered-dose inhalers (not larger than 0.8 μm)
[0123] The preparation steps for the metered-dose inhaler are the same as in Example 9. As shown in Table 10, the drug particles in this mixture are suspended in HFA-152a.
[0124] Table 10. Pressurized inhalation suspensions of salbutamol sulfate and budesonide, containing 1% w / w (by weight) lactose monohydrate and HFA-152a propellant.
[0125] Example 11: Contains two active particles, salbutamol sulfate and budesonide, and 1% w / w (weight percentage) lactose monohydrate (particle size distribution D). 90 No larger than 70μm, D 50 No larger than 31μm, D 10 Metered-dose inhalers (not larger than 1.5 μm)
[0126] The preparation steps for the metered-dose inhaler are the same as in Example 9. As shown in Table 11, the drug particles in this mixture are suspended in HFA-152a.
[0127] Table 11. Pressurized inhalation suspensions of salbutamol sulfate and budesonide, containing 1% w / w (by weight) lactose monohydrate and HFA-152a propellant.
[0128] Example 12: Contains two active particles, salbutamol sulfate and budesonide, and 0.1% w / w (weight percentage) lactose monohydrate (particle size distribution D). 90 No larger than 41μm, D 50 No larger than 16μm, D 10 Metered-dose inhalers (not larger than 2.7 μm)
[0129] The preparation steps for the metered-dose inhaler are as follows: First, weigh the required amount of the two active drug particles and 0.1% w / w (weight percentage) micronized lactose and place them in an FCP aluminum canister. After ultrasonically mixing for 10 minutes, seal the canister using the metering valve (crimping). Next, pour the required amount of HFO-1234ze(E) into the sealed FCP aluminum canister through the metering valve, and then ultrasonically mix for another 10 minutes. As shown in Table 12, the drug particles in this mixture are suspended in the HFO-1234ze(E) propellant.
[0130] Table 12. Pressurized inhalation suspensions of salbutamol sulfate and budesonide, containing 1% w / w (weight percentage) lactose monohydrate and HFO-1234ze(E) propellant.
[0131] Example 13: Contains two active particles, salbutamol sulfate and budesonide, and 1% w / w (weight percentage) lactose monohydrate (particle size distribution D). 90 No larger than 41μm, D 50 Metered-dose inhalers (not larger than 16 μm, D10 not larger than 2.7 μm)
[0132] The preparation steps for the metered inhaler are the same as in Example 12. As shown in Table 13, the drug particles in this mixture are suspended in HFO-1234ze(E).
[0133] Table 13. Pressurized inhalation suspensions of salbutamol sulfate and budesonide, containing 1% w / w (weight percentage) lactose monohydrate and HFO-1234ze(E) propellant.
[0134] This study compared the drug delivery efficacy of pressurized inhaled suspensions of salbutamol sulfate and budesonide using different formulations with HFA-152a propellant. The drug delivery amounts of different embodiments are shown in Table 14, expressed as a percentage of the actual delivered dose relative to the labeled delivered dose (108 mcg for salbutamol sulfate and 80 mcg for budesonide). (Based on the United States Pharmacopeia) <601> The total amount of drug collected from all DUSA devices (residual amount) divided by the total number of starts for each emission measurement should generally be within the range of not less than 85% and not more than 115% of the labeled delivery dose to meet the standard. Therefore, the pharmacopoeia stipulates that the drug delivery dose should not be less than 85% of the labeled dose. The compiled test results show that the commercially available control product also meets this standard; however, in Examples 7 to 9 and Examples 11, it was found that there was a high probability of blockage at the drug outlet, indicating the ejection of large particles, which was inferred to lead to excessive drug delivery; and the drug delivery results of the two products were also different, so they are not suitable for use in this application. In addition to the excessively large particle size, the results of Example 6 also showed that an excessive proportion of lactose could also cause the drug delivery to exceed the labeled delivery dose.
[0135] Table 14
[0136] Table 15 shows the aerodynamic particle size distribution (APSD) of salbutamol sulfate and budesonide in the commercially available products and the embodiments of this application, including fine particle dose (FPD), fine particle fraction (FPF), median mass aerodynamic diameter (MMAD), and laryngeal settling ratio. Surprisingly, using finer lactose to suspend the drug in HFA-152a can produce similar performance to the commercially available products, as in Examples 3, 4, and 5. While the salbutamol sulfate in Example 6 also performed similarly to the commercially available product, according to the drug delivery results shown in Table 15, the actual drug delivery dose exceeded the specified delivery dose, which does not comply with pharmacopoeia standards. This excessive dose indicates unstable drug delivery and also affects its particle distribution, as evidenced by the fact that the fine particle dose and fine particle fraction of budesonide were significantly lower than those of salbutamol sulfate in Example 6. Table 16 presents the stability data for the embodiments, with T0 indicating data before storage and 1M indicating data after one month of accelerated stabilization. During the experiment, the inventors found that when lactose was used as a carrier, the drug suspended in HFA-152a could have good stability; however, due to the unstable drug delivery in Examples 7 to 9 and Example 11, it was also found that there were unstable problems in the aerodynamic particle size distribution.
[0137] Table 15
[0138] Table 16
[0139] Based on the above results regarding drug delivery and particle size distribution, it can be seen that under specific lactose particle size and ratio, this application can obtain a product similar to commercially available products, which proves that this application has therapeutic effects.
[0140] In addition to HFA-152a, this application also studied another novel propellant, HFO-1234ze(E). However, as shown in Table 16, its effects are different from those of HFA-152a. After one month of accelerated stabilization, the formulation suspended in HFO-1234ze(E) showed a clear downward trend in drug fine particle dose (FPD), fine particle fraction (FPF), and various indicators, and the amount of drug deposited in the throat increased significantly.
[0141] This application provides inhaled pharmaceutical formulations and uses a metered-dose inhaler (MDI) for treating asthma and other chronic obstructive pulmonary diseases, and for delivering the medication to the treatment site. Therefore, this application includes the preparation of formulations for treating lung diseases in organisms (e.g., humans or animals), including administering the composition of this application containing a compound pharmaceutical product and an inhalation device to the organism in need of treatment. Although this application has been described and illustrated above with reference to certain preferred embodiments, this application is not necessarily limited to these examples and embodiments.
Claims
1. An inhaled pharmaceutical preparation comprising: Propellant; At least two active pharmaceutical ingredients; and Lactose or its hydrate; in, The particle size D of the lactose or its hydrate 90 No larger than 150μm, D 50 No larger than 75μm, D 10 No larger than 10μm.
2. The inhaled pharmaceutical formulation of claim 1, wherein the propellant is 1,1-difluoroethane (HFA-152a) or tetrafluoropropylene (HFO-1234ze(E)).
3. The inhaled pharmaceutical preparation of claim 1, wherein the active pharmaceutical ingredient is selected from a combination of at least two of the following: corticosteroids, beta-2 adrenergic agonists, anticholinergics, antiallergics, anti-inflammatories, bronchodilators, bronchoconstrictors, pulmonary lung surfactants, antibiotics, leukotriene inhibitors, leukotriene antagonists, mast cell inhibitors, and antihistamines, and any pharmaceutically acceptable salts thereof.
4. The inhaled pharmaceutical preparation of claim 1, wherein the concentrations of the at least two active pharmaceutical ingredients are both less than about 0.3% (w / w).
5. The inhaled pharmaceutical preparation of claim 1, wherein the lactose or its hydrate is present in the preparation at a concentration of about 0.1% (w / w) to about 1.5% (w / w).
6. The inhaled pharmaceutical preparation of claim 1, wherein the particle size D of the lactose or its hydrate is... 90 No larger than 50μm, D 50 No larger than 20μm, D 10 The content of lactose or its hydrate in the formulation is not greater than 5 μm, and the content is from about 0.8% (w / w) to about 1.2% (w / w).
7. The inhaled pharmaceutical preparation of claim 1, wherein the active pharmaceutical ingredient is a combination of a corticosteroid and a short-acting beta-glucose synergist; The corticosteroid drug mentioned above is selected from beclomethasone, budesonide, ciclesonide, flunisolone, fluticasone, methylprednisolone, mometasone, prednisone, triamcinolone, or any pharmaceutically acceptable salt thereof; The short-acting ethylenediamine synergist is selected from bitolterol, carbuterol, fenoterol, hexoprenaline, isoproterenol, levosabutamol, orciprenaline, pirbuterol, procaterol, rimitrol, salbutamol, terbutaline, tulobuterol, reproterol, ipratropium, epinephrine, or any pharmaceutically acceptable salt thereof.
8. The inhaled pharmaceutical formulation of claim 7, wherein the corticosteroid is budesonide, and its content in the formulation is from 0.18% (w / w) to 0.2% (w / w); and the short-acting beta-glycemic synergist is salbutamol sulfate, and its content in the formulation is from 0.25% (w / w) to 0.28% (w / w).
9. An inhalation device comprising: Actuator; and An aerosol can for filling an inhaled pharmaceutical preparation as described in any one of claims 1 to 8; The actuator includes a housing and a nozzle block for a metering valve; One end of the housing is open to accommodate the aerosol can, and the other end is open to form an airflow-through chamber for introducing the inhaled pharmaceutical preparation into the patient's oral cavity and / or nasal cavity. The nozzle block has an orifice channel that communicates with the dispensing valve and is used to guide the inhaled pharmaceutical preparation from the dispensing valve into the chamber.
10. Use of the inhaled pharmaceutical preparation according to any one of claims 1 to 8 for the preparation of a medicament for the treatment of lung diseases.
